Therapeutic or Preventive Procedure – Page 14

Trump Establishes Make America Healthy Again Commission to Combat Childhood Chronic Diseases

2 months ago talkbio0Tagged CHARGE Syndrome, Chronic disease, Commission, disease prevention, MAHA, public health medicine (field), Robert F. Kennedy Jr., Secretary

MAHA Commission, Robert F. Kennedy Jr., childhood chronic diseases, HHS Secretary, Executive Order, public health, chronic illness, disease prevention

Bristol Myers Squibb’s Opdualag Fails Phase 3 Trial in Adjuvant Melanoma Treatment

3 months ago talkbio0Tagged Clinical Trials, Failure (biologic function), Immunologic Adjuvants, Immunotherapy, Inhibitor, lymphocyte-activation gene 3 protein, human, melanoma, Myers, Opdualag, squibb

Opdualag, Bristol Myers Squibb, melanoma, clinical trial failure, LAG-3 inhibitor, immunotherapy, adjuvant treatment

FDA Approves Pfizer’s Adcetris Combination Therapy for Relapsed/Refractory Large B-cell Lymphoma

3 months ago talkbio0Tagged Adcetris, Antibody-Drug Conjugates, Approved, BRENTUXIMAB, Combined Modality Therapy, Diffuse Large B-Cell Lymphoma, LBCL, Pfizer, United States Food and Drug Administration, vedotin

Adcetris, brentuximab vedotin, FDA approval, large B-cell lymphoma, LBCL, DLBCL, antibody-drug conjugate, Pfizer, combination therapy

Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments

3 months ago talkbio0Tagged Anxiety Disorders, assets, Funding, GABA Modulators, mental health, Neuropsychiatry, Newleos, Roche (company), Series, Substance Use Disorders

Newleos Therapeutics, mental health, neuropsychiatry, Roche assets, Series A funding, anxiety disorders, substance use disorders, GABA modulators

Newleos Therapeutics Launches with $93.5M to Develop Novel Neuropsychiatric Treatments

3 months ago talkbio0Tagged Anxiety Disorders, Clinical Trials, GABA A, Longwood Fund, Neuropsychiatry, Newleos, Roche (company), Substance Use Disorders

Newleos Therapeutics, Longwood Fund, neuropsychiatry, anxiety disorders, substance use disorders, Roche, GABA A -γ1, clinical trials

AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial, Driving Stock Surge

3 months ago talkbio0Tagged AnaptysBio, Immunology, Increase, Prices, RENOIR, Rheumatoid Arthritis, Rosnilimab, Treatment Effectiveness

AnaptysBio, rosnilimab, rheumatoid arthritis, Phase 2b trial, RENOIR study, clinical efficacy, stock price increase, immunology therapeutics

AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies

3 months ago talkbio0Tagged AbbVie, Collaboration, Drug Development, engagers, Immunotherapy, Neoplasms, T-Lymphocyte, tumor-activated

AbbVie, Xilio Therapeutics, immunotherapy, tumor-activated, T cell engagers, collaboration, oncology, drug development

SpringWorks Therapeutics Secures FDA Approval for Gomekli to Treat NF1-Related Tumors

3 months ago talkbio0Tagged Approved, disease treatment, Gomekli, Infrequent, Inhibitor, MEK, mirdametinib, Neurofibromatosis 1, Plexiform, Plexiform Neurofibroma, SpringWorks, United States Food and Drug Administration

SpringWorks Therapeutics, Gomekli, mirdametinib, FDA approval, neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN), rare disease treatment, MEK inhibitor